Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

BACKGROUND: Cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection continue to rise in the Arabian Peninsula 7 years after it was first described in Saudi Arabia. MERS-CoV poses a significant risk to public health security because of an absence of currently available effective co...

Descripción completa

Detalles Bibliográficos
Autores principales: Folegatti, Pedro M, Bittaye, Mustapha, Flaxman, Amy, Lopez, Fernando Ramos, Bellamy, Duncan, Kupke, Alexandra, Mair, Catherine, Makinson, Rebecca, Sheridan, Jonathan, Rohde, Cornelius, Halwe, Sandro, Jeong, Yuji, Park, Young-Shin, Kim, Jae-Ouk, Song, Manki, Boyd, Amy, Tran, Nguyen, Silman, Daniel, Poulton, Ian, Datoo, Mehreen, Marshall, Julia, Themistocleous, Yrene, Lawrie, Alison, Roberts, Rachel, Berrie, Eleanor, Becker, Stephan, Lambe, Teresa, Hill, Adrian, Ewer, Katie, Gilbert, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science ;, The Lancet Pub. Group 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172901/
https://www.ncbi.nlm.nih.gov/pubmed/32325038
http://dx.doi.org/10.1016/S1473-3099(20)30160-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172901/
https://www.ncbi.nlm.nih.gov/pubmed/32325038
http://dx.doi.org/10.1016/S1473-3099(20)30160-2

Ejemplares similares